My Bibliography

select

Triplett O, Varda N, Decourt B, Vasconcellos R, Sabbagh MN. Active Immunization Targeting Amyloid β for the Treatment of Alzheimer's Disease. Neurodegener Dis. 2025 May 10;:1-16. doi: 10.1159/000546287. [Epub ahead of print] Review. PubMed PMID: 40349697; PubMed Central PMCID: PMC12363561.

select

Azarfar K, Decourt B, Sanchez Camacho B, Lawrence JJ, Omondi TR, Sabbagh MN. Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?. Expert Rev Neurother. 2025 May;25(5):521-535. doi: 10.1080/14737175.2025.2483928. Epub 2025 Apr 3. Review. PubMed PMID: 40140971; PubMed Central PMCID: PMC12068190.

select

Alam J, Sabbagh MN. Perspective: Minimally clinically important "symptomatic" benefit associated with disease modification resulting from anti-amyloid immunotherapy. Alzheimers Dement (N Y). 2025 Jan-Mar;11(1):e70035. doi: 10.1002/trc2.70035. eCollection 2025 Jan-Mar. PubMed PMID: 39839076; PubMed Central PMCID: PMC11746071.

select

Wicker A, Shriram J, Decourt B, Sabbagh MN. Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years. Neurol Ther. 2024 Dec;13(6):1571-1595. doi: 10.1007/s40120-024-00664-z. Epub 2024 Oct 8. Review. PubMed PMID: 39378014; PubMed Central PMCID: PMC11541067.

select

Ankeny SE, Bacci JR, Decourt B, Sabbagh MN, Mielke MM. Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications. Neurol Ther. 2024 Dec;13(6):1541-1557. doi: 10.1007/s40120-024-00658-x. Epub 2024 Sep 7. Review. PubMed PMID: 39244522; PubMed Central PMCID: PMC11541985.

select

Dunning EE, Decourt B, Zawia NH, Shill HA, Sabbagh MN. Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review. Neurol Ther. 2024 Aug;13(4):975-1013. doi: 10.1007/s40120-024-00614-9. Epub 2024 May 14. Review. PubMed PMID: 38743312; PubMed Central PMCID: PMC11263316.

select

Adem MA, Decourt B, Sabbagh MN. Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer's Disease. Biomedicines. 2024 Jan 3;12(1). doi: 10.3390/biomedicines12010099. Review. PubMed PMID: 38255204; PubMed Central PMCID: PMC10813018.

select

Sleem T, Decourt B, Sabbagh MN. Nonmedication Devices in Development for the Treatment of Alzheimer's Disease. J Alzheimers Dis Rep. 2024;8(1):241-255. doi: 10.3233/ADR-230115. eCollection 2024. Review. PubMed PMID: 38405349; PubMed Central PMCID: PMC10894612.

select

Noorda K, Noorda K, Sabbagh MN, Bertelson J, Singer J, Decourt B. Amyloid-Directed Antibodies: Past, Present, and Future. J Alzheimers Dis. 2024;101(s1):S3-S22. doi: 10.3233/JAD-240189. Review. PubMed PMID: 39422953; PubMed Central PMCID: PMC12312309.

select

Malaty GR, Decourt B, Shill HA, Sabbagh MN. Biomarker Assessment in Parkinson's Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures. J Alzheimers Dis Rep. 2024;8(1):1361-1371. doi: 10.3233/ADR-240110. eCollection 2024. PubMed PMID: 39493956; PubMed Central PMCID: PMC11530035.

select

Majeed J, Sabbagh MN, Kang MH, Lawrence JJ, Pruitt K, Bacus S, Reyna E, Brown M, Decourt B. Cancer drugs with high repositioning potential for Alzheimer's disease. Expert Opin Emerg Drugs. 2023 Dec;28(4):311-332. doi: 10.1080/14728214.2023.2296079. Epub 2023 Dec 26. Review. PubMed PMID: 38100555; PubMed Central PMCID: PMC10877737.

select

Vitek GE, Decourt B, Sabbagh MN. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opin Investig Drugs. 2023 Feb;32(2):89-94. doi: 10.1080/13543784.2023.2178414. Epub 2023 Feb 28. Review. PubMed PMID: 36749830; PubMed Central PMCID: PMC10275297.

select

Sabbagh MN, DeCourt B. Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic?. Nat Rev Neurol. 2023 Feb;19(2):71-72. doi: 10.1038/s41582-022-00767-x. PubMed PMID: 36627511; PubMed Central PMCID: PMC10342128.

select

Sabbagh MN, Taylor A, Galasko D, Galvin JE, Goldman JG, Leverenz JB, Poston KL, Boeve BF, Irwin DJ, Quinn JF. Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel. Alzheimers Dement (N Y). 2023 Jan-Mar;9(1):e12375. doi: 10.1002/trc2.12375. eCollection 2023 Jan-Mar. PubMed PMID: 36873923; PubMed Central PMCID: PMC9983146.

select

Sabbagh MN, Decourt B. COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease. Expert Opin Investig Drugs. 2022 Oct;31(10):987-993. doi: 10.1080/13543784.2022.2117605. Epub 2022 Sep 1. PubMed PMID: 36003033; PubMed Central PMCID: PMC10275298.

select

Decourt B, Sabbagh MN. The importance of genomics in advancing the diagnosis and treatment of dementia. Lancet Neurol. 2022 Aug;21(8):676-677. doi: 10.1016/S1474-4422(22)00234-4. Epub 2022 Jun 10. PubMed PMID: 35697056; PubMed Central PMCID: PMC10337990.

select

Decourt B, D'Souza GX, Shi J, Ritter A, Suazo J, Sabbagh MN. The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress. Aging Dis. 2022 Feb;13(1):37-60. doi: 10.14336/AD.2021.0529. eCollection 2022 Feb. PubMed PMID: 35111361; PubMed Central PMCID: PMC8782548.

select

Decourt B, Noorda K, Noorda K, Shi J, Sabbagh MN. Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia. J Exp Pharmacol. 2022;14:331-352. doi: 10.2147/JEP.S265626. eCollection 2022. Review. PubMed PMID: 36339394; PubMed Central PMCID: PMC9632331.

select

Decourt B, Boumelhem F, Pope ED 3rd, Shi J, Mari Z, Sabbagh MN. Critical Appraisal of Amyloid Lowering Agents in AD. Curr Neurol Neurosci Rep. 2021 Jun 10;21(8):39. doi: 10.1007/s11910-021-01125-y. Review. PubMed PMID: 34110536; PubMed Central PMCID: PMC8192384.

select

Pope ED, Cordes L, Shi J, Mari Z, Decourt B, Sabbagh MN. Dementia with Lewy bodies: emerging drug targets and therapeutics. Expert Opin Investig Drugs. 2021 Jun;30(6):603-609. doi: 10.1080/13543784.2021.1916913. Epub 2021 Apr 26. Review. PubMed PMID: 33899637; PubMed Central PMCID: PMC9169612.

select

Sabbagh M, Miller J, Jones S, Ritter A, Shi J, DeCourt B, Wint D. Does Informant-Based Reporting of Cognitive Decline Correlate with Age-Adjusted Hippocampal Volume in Mild Cognitive Impairment and Alzheimer's Disease?. J Alzheimers Dis Rep. 2021 Mar 11;5(1):207-211. doi: 10.3233/ADR-200260. PubMed PMID: 33981957; PubMed Central PMCID: PMC8075551.

select

Sadrolashrafi K, Craft S, Decourt B, Adem A, Wilson JR, Miller J, Sabbagh MN. Is diabetes associated with increased pathological burden in Alzheimer's disease?. Alzheimers Dement (Amst). 2021;13(1):e12248. doi: 10.1002/dad2.12248. eCollection 2021. PubMed PMID: 34796262; PubMed Central PMCID: PMC8579894.

select

Sabbagh MN, Pope E, Cordes L, Shi J, DeCourt B. Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD. Expert Opin Investig Drugs. 2021 Jan;30(1):39-44. doi: 10.1080/13543784.2021.1849138. Epub 2020 Dec 2. PubMed PMID: 33455481; PubMed Central PMCID: PMC9262379.

select

Sabbagh MN, Cummings J. Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019". Alzheimers Dement. 2021 Apr;17(4):702-703. doi: 10.1002/alz.12235. Epub 2020 Nov 1. PubMed PMID: 33135288; PubMed Central PMCID: PMC8043968.

select

Decourt B, Wilson J, Ritter A, Dardis C, DiFilippo FP, Zhuang X, Cordes D, Lee G, Fulkerson ND, St Rose T, Hartley K, Sabbagh MN. MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. Open Access J Clin Trials. 2020;12:1-13. doi: 10.2147/oajct.s221914. Epub 2020 Jan 7. PubMed PMID: 32123490; PubMed Central PMCID: PMC7051033.

select

Sabbagh MN. Editorial: Alzheimer's Disease Drug Development Pipeline 2020. J Prev Alzheimers Dis. 2020;7(2):66-67. doi: 10.14283/jpad.2020.12. PubMed PMID: 32236392; PubMed Central PMCID: PMC7437724.

select

Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opin Investig Drugs. 2019 Nov;28(11):951-965. doi: 10.1080/13543784.2019.1681398. Epub 2019 Oct 28. Review. PubMed PMID: 31614096; PubMed Central PMCID: PMC6823159.

select

Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B. Tau immunotherapies for Alzheimer's disease. Expert Opin Investig Drugs. 2019 Jun;28(6):545-554. doi: 10.1080/13543784.2019.1619694. Epub 2019 May 22. Review. PubMed PMID: 31094578; PubMed Central PMCID: PMC7169377.

select

Aslam S, Fritz MA, Cordes L, Sabbagh MN. What Promises the CJD Diagnosis in a Case of Rapidly Progressive Dementia?. J Alzheimers Dis Parkinsonism. 2018;8(5). doi: 10.4172/2161-0460.1000452. Epub 2018 Oct 30. PubMed PMID: 30733890; PubMed Central PMCID: PMC6362841.

select

Sabbagh M, Decourt B. Editorial: Current and Emerging Therapeutics in AD. Curr Alzheimer Res. 2017;14(4):354-355. doi: 10.2174/156720501404170217182758. PubMed PMID: 28240157; PubMed Central PMCID: PMC5705184.

select

Decourt B, Lahiri DK, Sabbagh MN. Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. Curr Alzheimer Res. 2017;14(4):412-425. doi: 10.2174/1567205013666160930110551. Review. PubMed PMID: 27697064; PubMed Central PMCID: PMC5328927.

select

Decourt B, Drumm-Gurnee D, Wilson J, Jacobson S, Belden C, Sirrel S, Ahmadi M, Shill H, Powell J, Walker A, Gonzales A, Macias M, Sabbagh MN. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial. Curr Alzheimer Res. 2017;14(4):403-411. doi: 10.2174/1567205014666170117141330. PubMed PMID: 28124585; PubMed Central PMCID: PMC5706445.

select

He Y, Ren Y, Wu B, Decourt B, Lee AC, Taylor A, Suter DM. Src and cortactin promote lamellipodia protrusion and filopodia formation and stability in growth cones. Mol Biol Cell. 2015 Sep 15;26(18):3229-44. doi: 10.1091/mbc.E15-03-0142. Epub 2015 Jul 29. PubMed PMID: 26224308; PubMed Central PMCID: PMC4569314.

select

Macias MP, Gonzales AM, Siniard AL, Walker AW, Corneveaux JJ, Huentelman MJ, Sabbagh MN, Decourt B. A cellular model of amyloid precursor protein processing and amyloid-β peptide production. J Neurosci Methods. 2014 Feb 15;223:114-22. doi: 10.1016/j.jneumeth.2013.11.024. Epub 2013 Dec 12. PubMed PMID: 24333289; PubMed Central PMCID: PMC3931259.

select

Decourt B, Mobley W, Reiman E, Shah RJ, Sabbagh MN. Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down Syndrome. J Alzheimers Dis Parkinsonism. 2013 Mar 20;Suppl 7:002. doi: 10.4172/2161-0460.S7-002. PubMed PMID: 24782952; PubMed Central PMCID: PMC4000700.

select

Decourt B, Gonzales A, Beach TG, Malek-Ahmadi M, Walker A, Sue L, Walker DG, Sabbagh MN. BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. Curr Alzheimer Res. 2013 Mar;10(3):309-15. doi: 10.2174/1567205011310030010. PubMed PMID: 23036023; PubMed Central PMCID: PMC4104947.

select

Decourt B, Walker A, Gonzales A, Malek-Ahmadi M, Liesback C, Davis KJ, Belden CM, Jacobson SA, Sabbagh MN. Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study. Platelets. 2013;24(3):235-8. doi: 10.3109/09537104.2012.688899. Epub 2012 Jul 9. PubMed PMID: 22775589; PubMed Central PMCID: PMC4000702.

select

Gonzales A, Decourt B, Walker A, Condjella R, Nural H, Sabbagh MN. Development of a specific ELISA to measure BACE1 levels in human tissues. J Neurosci Methods. 2011 Oct 30;202(1):70-6. doi: 10.1016/j.jneumeth.2011.08.030. Epub 2011 Aug 25. PubMed PMID: 21889954; PubMed Central PMCID: PMC3346260.

select

Decourt B, Sabbagh MN. BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis. 2011;24 Suppl 2(Suppl 2):53-9. doi: 10.3233/JAD-2011-110017. Review. PubMed PMID: 21403391; PubMed Central PMCID: PMC3313825.

select

Decourt B, Munnamalai V, Lee AC, Sanchez L, Suter DM. Cortactin colocalizes with filopodial actin and accumulates at IgCAM adhesion sites in Aplysia growth cones. J Neurosci Res. 2009 Apr;87(5):1057-68. doi: 10.1002/jnr.21937. PubMed PMID: 19021290; PubMed Central PMCID: PMC3241979.

select

Decourt B, Hillman D, Bouleau Y, Dulon D, Hafidi A. Is otospiralin inner ear specific? Evidence for its expression in mouse brain. Int J Dev Neurosci. 2009 Feb;27(1):87-96. doi: 10.1016/j.ijdevneu.2008.09.001. Epub 2008 Sep 11. PubMed PMID: 18832023.

select

Wu B, Decourt B, Zabidi MA, Wuethrich LT, Kim WH, Zhou Z, MacIsaac K, Suter DM. Microtubule-mediated Src tyrosine kinase trafficking in neuronal growth cones. Mol Biol Cell. 2008 Nov;19(11):4611-27. doi: 10.1091/mbc.e08-06-0603. Epub 2008 Aug 20. PubMed PMID: 18716055; PubMed Central PMCID: PMC2575181.

select

Lee AC, Decourt B, Suter D. Neuronal cell cultures from aplysia for high-resolution imaging of growth cones. J Vis Exp. 2008 Feb 20;(12). doi: 10.3791/662. PubMed PMID: 19066568; PubMed Central PMCID: PMC2582845.

select

Decourt B, Bouleau Y, Dulon D, Hafidi A. Expression analysis of neuroleukin, calmodulin, cortactin, and Rho7/Rnd2 in the intact and injured mouse brain. Brain Res Dev Brain Res. 2005 Sep 8;159(1):36-54. doi: 10.1016/j.devbrainres.2005.06.013. PubMed PMID: 16051374.

select

Decourt B, Bouleau Y, Dulon D, Hafidi A. Identification of differentially expressed genes in the developing mouse inferior colliculus. Brain Res Dev Brain Res. 2005 Sep 8;159(1):29-35. doi: 10.1016/j.devbrainres.2005.06.010. PubMed PMID: 16095723.

select

Hafidi A, Decourt B, MacLennan AJ. CNTFRalpha and CNTF expressions in the auditory brainstem: light and electron microscopy study. Hear Res. 2004 Aug;194(1-2):14-24. doi: 10.1016/j.heares.2004.04.004. PubMed PMID: 15276672.

select

Dubuisson L, Desmoulière A, Decourt B, Evadé L, Bedin C, Boussarie L, Barrier L, Vidaud M, Rosenbaum J. Inhibition of rat liver fibrogenesis through noradrenergic antagonism. Hepatology. 2002 Feb;35(2):325-31. doi: 10.1053/jhep.2002.31166. PubMed PMID: 11826405.